: Authors

Yousser Mohammad1* and Mohammad Osman Yusuf2

1Professor, Syrian Private University, Damascus and National Center for Research on Chronic Respiratory Diseases, Tishreen University,
Lattakia, Syria
2Chief Consultant, The Allergy and Asthma Institute, Pakistan

Received: June 13, 2017; Published: July 10, 2017

:Abstract

> Chronic Respiratory Diseases, especially asthma and COPD are a big burden (with more than 350 million asthmatics, and 65 million
COPD patients in the world); Causing morbidity, premature death, and economic negative impact [1]. If treated and managed appropriately, the quality of life and cost of disease, will improve at a personal, communal and a national level. These diseases need daily treatment
with inhalers: For asthma, we need inhaled corticosteroids (ICS), properly adjusted at different doses depending on the degree of control, attaining control may require add on  therapy to ICS like Beta2Long Acting Agonists (LABAs), Long Acting Muscarinic Agonists (LAMAs), and/or Leukotriene Receptor Antagonists (LTRAs). If there is an allergic  component to the asthma, assessment and removal of the cause of allergy, and supportive anti-allergy medications like treating allergic rhinitis and like immunotherapy may also be required to improve the quality of treatment and control